VanEck Pharmaceutical ETF PPH

Medalist Rating as of | See VanEck Investment Hub

Morningstar’s Analysis PPH

Will PPH outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

VanEck Pharmaceutical ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings PPH

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 71.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

20.79 212M
Healthcare

Merck & Co Inc

13.33 136M
Healthcare

Novo Nordisk AS ADR

5.59 57M
Healthcare

Pfizer Inc

5.14 53M
Healthcare

Bristol-Myers Squibb Co

4.85 50M
Healthcare

Teva Pharmaceutical Industries Ltd

4.77 49M
Healthcare

McKesson Corp

4.61 47M
Healthcare

GSK PLC ADR

4.44 45M
Healthcare

Cencora Inc

4.38 45M
Healthcare

AbbVie Inc

3.64 37M
Healthcare

Sponsor Center